Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 15Terminated 10Active not recruiting 6Recruiting 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × encorafenib × Clear all
NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡